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Abstract
Background: Biomarkers that allow detection of the onset of disease are of high interest since early detection would allow
intervening with lifestyle and nutritional changes before the disease is manifested and pharmacological therapy is required.
Our study aimed to improve the phenotypic characterization of overweight but apparently healthy subjects and to identify
new candidate profiles for early biomarkers of obesity-related diseases such as cardiovascular disease and type 2 diabetes.
Methodology/Principal Findings: In a population of 56 healthy, middle-aged overweight subjects Body Mass Index (BMI),
fasting concentration of 124 plasma proteins and insulin were determined. The plasma proteins are implicated in chronic
diseases, inflammation, endothelial function and metabolic signaling. Random Forest was applied to select proteins
associated with BMI and plasma insulin. Subsequently, the selected proteins were analyzed by clustering methods to
identify protein clusters associated with BMI and plasma insulin. Similar analyses were performed for a second population of
20 healthy, overweight older subjects to verify associations found in population I. In both populations similar clusters of
proteins associated with BMI or insulin were identified. Leptin and a number of pro-inflammatory proteins, previously
identified as possible biomarkers for obesity-related disease, e.g. Complement 3, C Reactive Protein, Serum Amyloid P,
Vascular Endothelial Growth Factor clustered together and were positively associated with BMI and insulin. IL-3 and IL-13
clustered together with Apolipoprotein A1 and were inversely associated with BMI and might be potential new biomarkers.
Conclusion/ Significance: We identified clusters of plasma proteins associated with BMI and insulin in healthy populations.
These clusters included previously reported biomarkers for obesity-related disease and potential new biomarkers such as IL-
3 and IL-13. These plasma protein clusters could have potential applications for improved phenotypic characterization of
volunteers in nutritional intervention studies or as biomarkers in the early detection of obesity-linked disease development
and progression.
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Introduction
Cardiovascular disease (CVD) and type 2 diabetes (T2DM) are
common disorders affecting millions of people worldwide.
Evidence is accumulating that chronic low-grade inflammation
plays a role in the development of both diseases [1,2]. Increased
plasma levels of several pro-inflammatory proteins and decreased
levels of anti-inflammatory proteins have been observed in subjects
with obesity and obesity-related diseases such as CVD and T2DM
[3,4,5,6].
Certain pro-inflammatory plasma proteins are used as diagnos-
tic biomarkers for disease state but specific plasma proteins may
also be used as biomarkers for early state in the development of a
disease. Such an improved pre-disease diagnostic would allow
intervening with relatively mild strategies such as lifestyle
interventions with specific dietary regimes and increased physical
activity in contrast to pharmacological therapy required once the
disease is manifested. Identification of biomarkers that allow
detection of the onset of disease will help in prevention of the
disease. Plasma proteins might be good candidates as they
circulate throughout the whole body, thereby reflecting total body
metabolic and inflammatory status. Moreover, blood can be easily
obtained from human subjects and therefore plasma proteins can
be easily measured for screening purposes.
So far, in most studies that investigated the use of plasma
proteins as biomarkers only a few plasma proteins were measured.
However, the etiology of diseases such as CVD and T2DM is
complex and the measurement of multiple biomarkers will provide
additional information about the individual phenotype and health
status as compared with measurement of a single biomarker [7,8].
Recent technological advances such as multiplex immunoassays
allow for the measurement of over hundred proteins at a time in
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one small plasma sample. Identification of biomarker profiles in
such large protein datasets requires advanced statistical analyses.
Random Forest (RF) has shown to be suitable for analysis of
complex data sets as derived from proteomics analysis [9,10]. RF
is a technique that can prioritize and select from a large number of
variables a set of variables that is likely to be related to the
outcome of interest. Furthermore, in the prioritization and
selection process, it provides a way to take interactions between
proteins into account [11,12]. The proteins that are selected by RF
can subsequently be analyzed by clustering methods, offering the
opportunity to identify clusters of proteins that are associated with
different health outcomes.
Our study aimed to improve the phenotypic characterization of
overweight but apparently healthy subjects and to identify new
candidate profiles for early biomarkers of obesity-related diseases
such as CVD and T2DM.
Methods
Subjects
Two populations were included in this study; population I was
the primary study population of interest and population II was a
smaller population used for verification of the results found in
population I.
Population I consisted of 56 healthy men and women who
participated in a controlled feeding trial [13]. Subjects included
were aged 40–65 years with a BMI$25 kg/m2 or a waist
circumference $94 cm for men and $80 cm for women.
Excluded were hypercholesterolemic subjects (fasting total choles-
terol $8 mmol/L) and subjects with non-treated diabetes mellitus
(according to WHO criteria) as measured by an oral glucose
tolerance test during screening. Other exclusion criteria were the
use of serum lipid or blood pressure lowering medication.
Population II consisted of 20 healthy, independently living
elderly men and women. This population is a subgroup of the
population participating in the study of Van de Rest et al. [14].
Subjects included were aged .65 years without depression,
dementia or serious liver disease. This population was chosen
because subjects were healthy and had average BMI and insulin
values comparable to those from population I.
Both studies were approved by the Medical Ethics Committee
of Wageningen University and all subjects gave written informed
consent.
Plasma proteins
In population I, concentrations of 124 proteins, including
insulin, were measured in fasting plasma by quantitative multiplex
immunoassay based on Luminex xMAP technology (Rules Based
Medicine Inc, Austin, Texas, USA) according to the procedure
described by Domenici et al. [15–16]. For each multiplex, both
calibrators and controls were included on each microtiter plate. 8-
point calibrators were run in the first and last column of each plate
and 3-level controls were included in duplicate. Testing results
were determined first for the high, medium and low controls for
each multiplex to ensure proper assay performance. Unknown
values for each of the analytes localized in a specific multiplex were
determined using 4 and 5 parameter, weighted and non-weighted
curve fitting algorithms included in the data analysis package. The
plasma samples were run in duplicate and data reported as
concentrations (average of two independent measures), together
with data for the least detectable dose (LDD). Any value above the
LDD will possess coefficients of variation (CV) less than 20%.
Rules-Based Medicine’s Multi-Analyte Profiles have been validat-
ed to Clinical Laboratory Standards Institute guidelines.
The set of proteins present on the assay consists of factors that
are implicated in chronic diseases, inflammation, endothelial
function and metabolism. In table S1 all proteins measured are
listed.
Before analysis 16 out of 124 proteins (figure S1) were removed
from the dataset as the concentrations of these proteins were below
the detection limit in more than half of the samples. For the
Table 1. Characteristics of the study populations.
Population I (n =56) Population II (n = 20)
Sex (m/f) 23/33 10/10
Age (years) * 56.466.7 70.163.1
BMI (kg/m2) 27.465.0 28.365.4
Smokers (%) 11% 10%
Waist circumference (cm) 96.9613.2 99.0613.8
Insulin (pmol/L) 16.1168.84 14.2468.05
Data is displayed as mean 6 standard deviation.
*Significantly different between the populations, p,0.05.
doi:10.1371/journal.pone.0014422.t001
Table 2. Association of proteins with BMI in the two
populations.
Population I (n=56) Population II (n = 20)
Protein Im RF
Spearman
correlation Im RF
Spearman
correlation
1. Leptin 71.8 0.47 ** 39.4 0.76 **
2. MCSF 49.1 0.18 n.d. n.d.
3. IL-3 42.8 20.43 ** 11.7 20.67 **
4. Insulin 35.4 0.48 ** 51.4 0.74 **
5. Apo A1 33.0 20.48 ** 24.4 20.66 **
6. IL-13 25.7 20.46 ** 26.1 20.57 **
7. PAI-1 19.7 0.48 ** 22.7 0.63 **
8. Eotaxin 17.2 20.40 ** ,5 20.29
9. CA19-9 16.2 20.06 ,5 0.30
10. CRP 15.0 0.46 ** 10.4 0.60 **
11. MDC 14.4 0.20 ,5 0.01
12. Resistin 14.1 0.27 * ,5 0.37
13. IL-6 11.4 0.42 ** n.d. n.d.
14. Apo B 11.1 0.20 n.d. n.d.
15. SAP 8.6 0.38 ** 34.6 0.70 **
16. C3 8.5 0.42 ** 36.5 0.48 *
17. MIP1b 7.5 0.25 ,5 0.31
18. VEGF 6.1 0.38 ** 22.8 0.59 **
19. FABP 5.4 0.20 ,5 0.11
20. LPA 5.2 0.26 * ,5 20.11
*p,0.05, ** p,0.005.
Abbreviations: not determined (n.d.), Importance Index Random Forest (Im RF),
Macrophage colony-stimulating factor (MCSF), Apolipoprotein A1 (ApoA1),
Plasminogen Activator Inhibitor-1 (PAI-1), Cancer Antigen 19-9 (CA 19-9), C
Reactive Protein (CRP), Macrophage Derived Chemokine (MDC), Apolipoprotein
B (ApoB), Serum Amyloid P (SAP), Complement 3 (C3), Macrophage
Inflammatory Protein-1 beta (MIP1b), Vascular endothelial growth factor (VEGF),
Fatty Acid Binding Protein (FABP), Lipoprotein A (LPA).
doi:10.1371/journal.pone.0014422.t002
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remaining 108 proteins, values below the detection limit were
replaced by 0.1*Least Detectable Dose. As IL-6 was one of the
removed proteins and IL-6 is an important factor for obesity and
diabetes [6], this protein was separately measured by high-sensitive
enzyme immunoassay (Human IL-6 Quantikine HS ELISA Kit,
R&D Systems, Abingdon, United Kingdom). Apo lipoprotein B
(ApoB) was not included in the Human Multi-Analyte Profiles,
and ApoB levels were additionally measured on a Hitachi 912
autoanalyser (Roche, Lelystad, The Netherlands) using a com-
mercially available kit (Roche cat. nr.1551779). In population II,
the plasma concentrations of 107 out of the 124 proteins measured
in population I, were determined using multiplex immunoassay
(Rules Based Medicine Inc, Austin, Texas, USA) (table S1). In
total, 110 proteins were included in the analysis for population I
and 90 proteins were included in the analysis for population II
(figure S1).
Statistical analyses
Univariate analyses. The association between individual
protein concentrations, BMI and plasma insulin concentration was
calculated by univariate analysis. The statistical package PASW
(version 17.0; SPSS, Chicago, IL) was used for the univariate
analysis. Since the distribution of several variables was slightly
skewed in the population, Spearman correlation coefficients were
calculated for the association between protein concentrations,
BMI and insulin concentrations.
Random Forest. Random Forest (RF) was used to provide a
ranking in the importance of proteins in their relationship with
BMI as well as with plasma insulin concentrations, taking possible
interactions between proteins into account. The R package
randomForest (R-package randomForest, http://cran.r-project.
org/), which is based on the original FORTRAN code from
Breiman et al. [11] was used for the analysis (www.stat.berkeley.
edu/˜breiman/RandomForests/).
In RF a group of tree-based models (the forest) is used to rank
the proteins with an important contribution to BMI or insulin
values [12,17]. Each tree starts with the total data set, which is split
into smaller and more homogeneous groups to fit models for
predicting the outcome from the measured proteins. Within the
forest, different trees are obtained by bootstrap sampling and
random subset selection.
Importance of proteins in association with the outcome of
interest is defined by a measure referred to as the importance
index, Im. For each protein, this Im is obtained by comparing the
predictive performance of the forest for all proteins with the
predictive performance of the forest in which the values of the
protein are randomly permuted in the trees for the left-out
observations. Larger differences in the predictive performance give
a larger Im, indicating that the protein is more important. By
permuting the values for one protein, not only the effect of this
protein is taken into account, but also all possible interactions of
this protein with other proteins. Interactions between proteins
Figure 1. Correlation matrix of selected proteins associated with BMI in population I (A) and II (B). Correlation coefficients are displayed
on a color scale, ranging from 20.6 (green) to 0.6 (red). For population I (A) 20 proteins selected by RF to be associated with BMI are included. This
group of proteins was divided in three clusters based on similarity in the association with BMI and with each other. For population II (B) 10 proteins
selected by RF and also associated with BMI in population I are included. This group of proteins was divided in two clusters based on similarity in the
association with BMI and with each other. Abbreviations: Cancer Antigen 19-9 (CA 19-9), Apolipoprotein A1 (ApoA1), Fatty Acid Binding Protein
(FABP), Macrophage Inflammatory Protein-1 beta (MIP1b), Apolipoprotein B (ApoB), Lipoprotein A (LPA), Macrophage Derived Chemokine (MDC),
Macrophage colony-stimulating factor (MCSF), Complement 3 (C3), C Reactive Protein (CRP), Serum Amyloid P (SAP), Plasminogen Activator Inhibitor-
1 (PAI-1), Vascular endothelial growth factor (VEGF).
doi:10.1371/journal.pone.0014422.g001
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increase the Im for each of the proteins that are part of the
interaction. Thus, in the ranking of proteins by their importance
RF takes interactions between proteins into account.
To perform the RF analyses we used the scaled mean decrease
in prediction accuracy. To obtain stable estimates of the Im and to
capture as many important interactions as possible, the analyses
were performed with a large number of trees (40,000). Im was used
as measure to rank the proteins. We chose not to apply a FDR
estimation of the Im scores, because FDR estimation of
importance scores derived by tree-based approaches usually
overestimates the real FDR it can lead to an unreliable selection
of a subset of variables [18].
For RF analysis a threshold value of significance does not exist.
In this study a threshold was set at an Im of 5 and only proteins
with an Im.5 were considered for subsequent cluster analyses. We
chose for this liberal threshold to avoid the possibility of leaving
out proteins that might be of importance in relation to BMI and
insulin.
Clustering of the proteins
The program MultiExperimentViewer, version 4.3 was used for
hierarchical clustering and visualization of the data [19].
Hierarchical clustering organizes the data into a binary tree that
groups similar elements together. Proteins, BMI and insulin were
clustered based on their Spearman correlation coefficients to select
groups of proteins with high correlation with BMI or insulin and
with each other. Besides clustering of the proteins with BMI and
proteins with insulin based on their correlation coefficients also
individual protein profiles were clustered based on similarities in
protein concentrations. To compare the individual protein
concentrations, z-scores were calculated for each individual
protein
x{m
s
 
.
To compare the association of the identified clusters of proteins
and BMI to the association of single traditional biomarkers and
BMI regression analysis was performed using the statistical
package PASW (version 17.0; SPSS, Chicago, IL).
Pathway analysis
Ingenuity Pathways Analysis, version 8.7 (IngenuityH Systems,
www.ingenuity.com) was used to identify connections between
proteins and canonical pathways and diseases that were most
significant to the data. Proteins were entered in Ingenuity based on
their Swiss Prot ID and only connections, both direct and indirect,
between proteins for humans and human primary cells were
considered in the analysis.
Results
Baseline characteristics
Characteristics of the two study populations used in the analysis
are displayed in table 1. BMI, waist circumference, insulin levels
and percentage smokers were comparable in the two populations
and age was significantly higher (13.761.1) in population II.
Plasma protein concentrations for both populations are
displayed in table S2.
Associations of proteins with BMI
In population I the RF Im of 20 proteins was above 5 and these
proteins were considered to be associated with BMI (table 2).
Using univariate analysis, 14 out of these 20 selected proteins
Figure 2. Clustering of personal profiles of robustly positively BMI-associated proteins in population I (A) and II (B). Protein values are
displayed on a color scale; red indicates higher values than group average, green indicated lower values than group average. The personal BMI values
are displayed on a separate color scale; green for BMI,25, black for BMI 25–30 and red for BMI.30. Only robustly positively BMI-associated proteins
from cluster 1, as identified by RF and cluster analysis, were included in this figure.
doi:10.1371/journal.pone.0014422.g002
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correlated significantly with BMI (table 2). For these 20 proteins
and BMI mutual correlation coefficients were calculated. Based on
these correlation coefficients a correlation matrix was constructed
in which the proteins and BMI were clustered by similarity in their
correlations (figure 1A). Using this approach, three clusters of
proteins associated with BMI could be identified; cluster 1 and 3
were positively associated with BMI while cluster 2 was negatively
associated with BMI. Cluster 1 showed robust associations with
BMI and contains proteins highly positively associated with BMI
and with each other and included insulin, leptin, Complement 3
(C3), Interleukin 6 (IL-6), C Reactive Protein (CRP), Plasminogen
Activator Inhibitor (PAI-1), Serum Amyloid P (SAP) and Vascular
Endothelial Growth Factor (VEGF). Cluster 2 also showed robust
associations with BMI and the included proteins were inversely
associated with BMI and positively with each other (figure 1A) and
contained the proteins Apolipoprotein A1 (ApoA1), Cancer
Antigen 19-9 (CA 19-9), Eotaxin, IL-3 and IL-13. The third
cluster includes proteins that were positively associated with BMI
and each other but most of these associations were less
pronounced than in clusters 1 and 2.
In population II 22 proteins were associated with BMI, based on
RF Im above 5, of which ten proteins were also associated with
BMI in population I (table 2 and figure S1). A correlation matrix
of these ten proteins and BMI was made for population II.
Clustering of the proteins in population II was similar to the
clustering in population I (figure 1A and 1B). The protein clusters
1 and 2, which showed robust associations in population I, were
also associated with BMI in population II. The weaker associations
of protein cluster 3 could not be confirmed. Associations in
population II were more robust compared to associations in
population I.
Regression analysis to compare the association of the identified
clusters of proteins and BMI to the association of single traditional
biomarkers such as CRP and IL-6 showed that the explained
variance was higher when all proteins of cluster 1 were included in
the model compared to when only IL6 or CRP or a combination
of both were included. For BMI, the proportion of variance
explained was 16.3% for IL-6 alone, 19.4% for CRP alone, 22.0%
for CRP and IL-6 combined, and 32.3% when all proteins from
cluster 1 were included in the model. For insulin, cluster 1
explained 25.6% of the variance, compared to 8.3% by CRP
alone, 11.8% by IL-6 alone, and 12.0% by CRP and IL-6
combined.
Out of the cluster analysis we selected the highly BMI-
associated proteins from cluster 1 to plot individual plasma
profiles (figure 2). Subjects with similar plasma protein concen-
trations were clustered and their BMI values were subsequently
displayed. Figure 2 shows that, as expected, in general persons
with higher BMI have higher concentrations of the selected
proteins. However, a few persons with BMI values ,25 kg/m2
had high plasma levels of these proteins and a few persons with
BMI values .30 kg/m2 had low plasma protein levels.
Association of proteins with insulin concentration
The association between protein profiles and fasting insulin
concentration was investigated using the same approach as for
BMI. In population I, RF analysis identified 20 proteins that were
considered to be associated with insulin concentration (table 3).
Using univariate analysis, ten of these proteins significantly
correlated with insulin concentration. Hierarchical clustering of
the 20 selected proteins and insulin based on correlation
coefficients resulted in the formation of four separate protein
clusters (figure 3A). The proteins forming cluster 1, 2 and 3 were
all positively associated with insulin concentration and the proteins
in the fourth cluster were negatively associated with insulin.
In population II, 9 out of the 20 selected proteins in population I
were associated with plasma insulin concentrations (table 3,
figure 3B and figure S1). As for BMI associations with insulin in
population II were more robust compared to associations with
insulin in population I.
Pathway analysis
An overview of all clusters of proteins and interactions between
the single proteins selected by RF is displayed in figure 4. This
figure also shows the top 5 most significant pathways and diseases
for the BMI- and insulin-associated proteins. Acute phase response
signaling was the most significant pathway for BMI-associated
proteins and was also significant for insulin-associated proteins.
Discussion
Elevated plasma levels of several pro-inflammatory proteins are
related to the development of obesity-linked diseases, in particular
to T2DM and CVD [4,20,21,22]. In the current study we
observed associations of clusters of pro- and anti-inflammatory
Table 3. Association of proteins with fasting plasma insulin in
both populations.
Population I (N=56) Population II (N=20)
Protein Im RF
Spearman
correlation Im RF
Spearman
correlation
1. SAP 42.9 0.518** 25.8 0.579*
2. Leptin 32.2 0.333* 23.3 0.695**
3. PAP 29.2 0.411** ,5 20.165
4. MIP1b 28.8 0.376** ,5 0.104
5. C3 18.5 0.379** 29.0 0.621**
6. IL-7 16.9 0.077 ,5 20.492*
7. FABP 16.8 0.416** ,5 0.099
8. ASP 16.0 0.383** ,5 0.220
9. VEGF 11.1 0.296* 21.3 0.590*
10. CK_MB 10.0 0.040 41.8 20.614*
11. TNFa 9.9 0.250 ,5 0.340
12. MPO 9.0 0.257 30.4 0.450*
13. IL-6 8.0 0.363** n.d. n.d.
14. PP 7.8 20.171 ,5 20.219
15. Apo CIII 7.5 20.240 ,5 20.072
16. ENA-78 7.2 0.082 5.5 0.520*
17. Factor VII 6.8 0.243 10.9 0.460*
18. IL-8 6.1 0.149 ,5 0.155
19. IL-18 5.8 0.230 ,5 20.169
20. CRP 5.1 0.317* 36.6 0.723**
*p,0.05, ** p,0.005.
Abbreviations: Importance factor Random Forest analysis (Im RF), not
determined (n.d), Serum Amyloid P (SAP), Prostatic Acid Phosphatase (PAP),
Macrophage Inflammatory Protein-1 beta (MIP1b), Complement 3 (C3), Fatty
Acid Binding Protein (FABP), Acylation Stimulating Protein (ASP), Vascular
endothelial growth factor (VEGF), Creatine Kinase-MB (CK-MB), Tumor Necrosis
Factor alpha (TNFa), Myeloperoxidase (MPO), Pancreatic Polypeptide (PP),
Apolipoprotein CIII (Apo CIII), Epithelial neutrophil-activating peptide 78 (ENA-
78), C Reactive Protein (CRP).
doi:10.1371/journal.pone.0014422.t003
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proteins with BMI and insulin in a presumably healthy population.
These BMI- and insulin-associated protein clusters may serve as
biomarkers for a pre-disease state of people at risk to develop CVD
and T2DM. The protein clusters could possibly be used to
improve individual disease risk prediction and help in the design of
personalized strategies to prevent disease as early as possible.
The protein cluster showing the most robust positive association
with BMI contained a number of pro-inflammatory proteins of
which several are involved in the acute phase response, such as
CRP, IL-6, C3 and SAP. These and other proteins (i.e. ASP,
MPO, PAI-1 and VEGF) included in this cluster and in cluster 1
that was associated with insulin were previously found to be
increased in subjects with insulin resistance, CVD, or both
[3,21,23,24,25,26,27,28,29,30,31,32]. From prospective studies
evidence has accumulated that increased levels of C3 and CRP
can predict T2DM and coronary events and could be candidate
biomarkers for a pathological state preceding the ultimate disease
[3,8,26,27]. We hypothesize that the proteins clustering together
with CRP and C3 could be similar type of biomarkers. Moreover,
Macrophage Colony-Stimulating Factor (MCSF) which was highly
positively associated with BMI was discovered to be a prognostic
marker of cardiovascular events in patients with chronic coronary
artery disease [33]. We speculate that MCSF may also be an early
biomarker for cardiac disease in healthy subjects.
The positive correlations of BMI with leptin and other
adipose-tissue derived proteins, as seen in our study, supports
the view of adipose tissue as an important source of immune-
related proteins [34]. However, besides adipose tissue-derived
proteins also proteins produced by the liver, endothelial cells,
immune cells and lipoproteins were associated with BMI and
insulin in our healthy subjects. This indicates that low-grade
inflammation in the early disease state is not only an adipose
tissue-specific effect but that also organ cells increase their
secretion of inflammatory proteins with increasing BMI or
plasma insulin levels.
A small cluster of proteins (ApoA1, CA19-9, Eotaxin, IL-3 and
IL-13) was negatively associated with BMI. Plasma levels of tumor
marker CA19-9 and ApoA1, the major protein component of
plasma HDL, were reported to be lower in obesity [35,36]. Less is
known about the negative association of BMI with Th2 cytokines
IL-3 and IL-13 and Eotaxin, which are correlated with each other
and closely clustered [37,38,39]. Concentrations of IL-3 and IL-13
were on average very low in the populations so we should be
careful with the interpretation of this data. Nevertheless we
observed associations of IL-3 and IL-13 with BMI in both study
populations, therefore these proteins might be considered as
potential new early biomarkers for obesity-related diseases.
Associations between strongly associated protein clusters 1 and
2 with BMI and insulin in the primary study population were
confirmed in the second population. Weaker associations were not
all confirmed which could be attributable to the lower number of
subjects in population II and the fact that less proteins were
measured reducing the chance of finding protein interactions with
RF. However, the strong associations found in population I were
Figure 3. Correlation matrix of selected proteins associated with insulin in population I (A) and II (B). Correlation coefficients are
displayed on a color scale, ranging from20.6 (green) to 0.6 (red). For population I (A) 20 proteins selected by RF to be associated with fasting plasma
insulin are included. This group of proteins was divided in four clusters based on similarity in the association with insulin and with each other. For
population II (B) 9 proteins selected by RF and also associated with BMI in population I are included. This group of proteins was divided in three
clusters based on similarity in the association with insulin and with each other. Abbreviations: Creatine Kinase-MB (CK-MB), Pancreatic Polypeptide
(PP), Prostatic Acid Phosphatase (PAP), Fatty Acid Binding Protein (FABP), Vascular endothelial growth factor (VEGF), Macrophage Inflammatory
Protein-1 beta (MIP1b), Tumor Necrosis Factor alpha (TNFa), Epithelial neutrophil-activating peptide 78 (ENA-78), Apolipoprotein CIII (Apo CIII),
Complement 3 (C3), Acylation Stimulating Protein (ASP), Myeloperoxidase (MPO), Serum Amyloid P (SAP), C Reactive Protein (CRP).
doi:10.1371/journal.pone.0014422.g003
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even more pronounced in population II. The latter population was
significantly older but concentrations of individual plasma pro-
inflammatory proteins were not higher. Maybe an elevated BMI
or insulin concentration in elderly subjects is directly linked to an
increase in pro-inflammatory protein secretion while this is not
always the case in younger subjects who may display a more
flexible metabolic phenotype in handling changes in BMI or
insulin concentration.
Levels of individual proteins were not extremely elevated in our
study subjects, but based on protein profiles subjects may be
differentially classified with lower or higher risk to develop a more
pathological phenotype. Despite the fact that the risk profile was
BMI-related in the whole study population, there were a few
subjects with low BMI also having this risk profile and a few
subjects with high BMI not having the profile. Besides BMI, waist-
to-height ratio can be used as a determinant for obesity-related
health risk. When the same analyses were performed for the
association of proteins with waist-to-height ratio similar results as
for BMI were found. Our findings support the recent ideas of using
a ‘multimarker’ approach, i.e. measuring multiple plasma proteins
in instead of single biomarkers or only BMI to increase the
prognostic value for individual disease risk [8,40,41].
Still, the measurement of multiple proteins makes data analysis
complex and calls for more advanced methods of data analysis.
Using RF we were able to identify associations of proteins with
BMI or insulin that were not observed when associations of each
protein were analyzed separately, but combined with other
proteins may be of relevance. For RF we chose a liberal threshold
for selection of proteins associated with BMI or insulin, which
increases the risk of selecting proteins that are not related to the
outcome of interest. However, using this threshold, we observed a
high overlap between the results from RF and univariate analysis.
Furthermore, we applied this analysis to two independent
populations to replicate and verify the associations of protein
clusters with BMI and insulin. In our view, this approach has
increased the reliability of our results.
The results of our study are based on a single measurement of
plasma proteins that provides a ‘‘snapshot’’ of the actual health
status. Whether it can be used in predicting long-term health and
inflammatory status requires more long-term studies. Further-
more, our primary study population consisted of a relatively low
number of subjects. However, we have observed associations of
proteins with BMI or insulin that are physiologically relevant and
were found in epidemiological and clinical studies
[3,5,6,8,21,23,24,31,32]. Moreover, we were able to confirm the
most robust associations in a second, even smaller population
consisting of subjects from a different age group.
With our study it is not possible to draw conclusions about the
causal relationship between elevated concentrations of the selected
proteins and occurrence of disease. Further prospective studies
with clinical end points are needed to determine whether the
protein clusters found in this study could be used as reliable
Figure 4. BMI- and insulin-associated proteins, their interactions and pathways and diseases in which they are involved. All defined
clusters of BMI and insulin-associated proteins are displayed, in red the positively associated clusters and in green the negatively associated clusters.
In dark red or green BMI and insulin-associated proteins in both populations are shown, in light red and light green only the BMI and insulin-
associated proteins in population I. Connections between proteins and the top 5 canonical pathways and diseases relevant to the data are shown.
Abbreviations: Triggering Receptor Expressed on Myeloid cells 1 (TREM1).
doi:10.1371/journal.pone.0014422.g004
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biomarkers for early identification of persons at risk for T2DM
and CVD.
Our study aimed at identifying new leads for clusters of early
biomarkers of disease by using plasma protein profiling in healthy
subjects. In healthy subjects we identified clusters of proteins
associated with BMI and insulin that included previously identified
biomarkers for obesity-related disease risk and potential new
biomarkers for which an association with disease is not well-
established. We showed that plasma protein profiling allows a
more subtle phenotypic characterization and differentiation of
people with otherwise similar phenotypical features such as BMI
or insulin levels. This could be of great value for dietary and
pharmacological intervention studies where subgroups of volun-
teers with matching phenotypes could be included in order to
improve the power of such interventions. Improved individual risk
assessment and classification of subjects may ultimately lead to a
more tailored and adequate intervention either by pharmacology
or changes in lifestyle.
Supporting Information
Table S1 Proteins included in the analysis for both populations.
‘+’ indicates that the protein is measured and detected in more
than half of the samples and included in the analysis. ‘-’ indicates
that the protein is not measured or not detected in more than half
of the samples and therefore not included in the analysis.
Found at: doi:10.1371/journal.pone.0014422.s001 (0.14 MB
DOC)
Table S2 Protein concentrations in each population Concen-
trations are displayed as mean 6 standard deviation. Abbrevia-
tions: not determined (n.d.)
Found at: doi:10.1371/journal.pone.0014422.s002 (0.14 MB
DOC)
Figure S1 Overview of selection of proteins for analysis in both
populations
Found at: doi:10.1371/journal.pone.0014422.s003 (0.12 MB TIF)
Acknowledgments
The authors thank Dr. E.H.J.M. Jansen (National Institute for Public
Health and the Environment, RIVM, Bilthoven, Netherlands) for technical
support.
Author Contributions
Conceived and designed the experiments: EF JMG LdG MM LAA.
Performed the experiments: SJvD MBB OvdR. Analyzed the data: SJvD
AGH. Wrote the paper: SJvD. Revised the article critically for important
intellectual content: LAA EF AGH MBB OvdR JMG LdG MM.
References
1. Festa A, D’Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, et al. (2000)
Chronic subclinical inflammation as part of the insulin resistance syndrome: the
Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42–47.
2. Koenig W, Khuseyinova N (2007) Biomarkers of atherosclerotic plaque
instability and rupture. Arterioscler Thromb Vasc Biol 27: 15–26.
3. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, et al. (2005) C-
reactive protein and the 10-year incidence of coronary heart disease in older
men and women: the cardiovascular health study. Circulation 112: 25–31.
4. Trayhurn P, Wood IS (2005) Signalling role of adipose tissue: adipokines and
inflammation in obesity. Biochem Soc Trans 33: 1078–1081.
5. Warnberg J, Nova E, Moreno LA, Romeo J, Mesana MI, et al. (2006)
Inflammatory proteins are related to total and abdominal adiposity in a healthy
adolescent population: the AVENA Study. Am J Clin Nutr 84: 505–512.
6. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, et al. (2001)
Circulating interleukin-6 in relation to adiposity, insulin action, and insulin
secretion. Obes Res 9: 414–417.
7. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT
(2008) Inflammatory and non-invasive vascular markers: the multimarker
approach for risk stratification in coronary artery disease. Atherosclerosis 199:
3–11.
8. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, et al. (2003)
Inflammatory markers and onset of cardiovascular events: results from the
Health ABC study. Circulation 108: 2317–2322.
9. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, et al. (2009) The multiplex bead
array approach to identifying serum biomarkers associated with breast cancer.
Breast Cancer Res 11: R22.
10. Barrett JH, Cairns DA (2008) Application of the random forest classification
method to peaks detected from mass spectrometric proteomic profiles of cancer
patients and controls. Stat Appl Genet Mol Biol 7: Article4.
11. Breiman L (2001) Random Forest. Machine Learning 45: 5–32.
12. Rodenburg W, Heidema AG, Boer JM, Bovee-Oudenhoven IM, Feskens EJ,
et al. (2008) A framework to identify physiological responses in microarray-based
gene expression studies: selection and interpretation of biologically relevant
genes. Physiol Genomics 33: 78–90.
13. Bos MB, de Vries JH, Feskens EJ, van Dijk SJ, Hoelen DW, et al. (2009) Effect of
a high monounsaturated fatty acids diet and a Mediterranean diet on serum
lipids and insulin sensitivity in adults with mild abdominal obesity. Nutr Metab
Cardiovasc Dis.
14. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Hoefnagels WH, et al.
(2008) Effect of fish-oil supplementation on mental well-being in older subjects: a
randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 88:
706–713.
15. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, et al. (2010) Plasma
protein biomarkers for depression and schizophrenia by multi analyte profiling
of case-control collections. PLoS One 5: e9166.
16. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, et al. (2009)
Quantification of cardiovascular biomarkers in patient plasma by targeted mass
spectrometry and stable isotope dilution. Mol Cell Proteomics 8: 2339–2349.
17. Heidema AG, Feskens EJ, Doevendans PA, Ruven HJ, van Houwelingen HC,
et al. (2007) Analysis of multiple SNPs in genetic association studies: comparison
of three multi-locus methods to prioritize and select SNPs. Genet Epidemiol 31:
910–921.
18. Huynh T, Wehenkel L, Geurts P (2008) Exploiting tree-based variable
importances to selectively identify relevant variables. Journal of Machine
Learning Research Workshop and Conference Proceedings 4: 60–73.
19. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4
microarray software suite. Methods Enzymol 411: 134–193.
20. Tracy RP (1999) Inflammation markers and coronary heart disease. Curr Opin
Lipidol 10: 435–441.
21. Festa A, D’Agostino R, Jr., Tracy RP, Haffner SM (2002) Elevated levels of
acute-phase proteins and plasminogen activator inhibitor-1 predict the
development of type 2 diabetes: the insulin resistance atherosclerosis study.
Diabetes 51: 1131–1137.
22. Haffner SM (2003) Pre-diabetes, insulin resistance, inflammation and CVD risk.
Diabetes Res Clin Pract 61 (Suppl 1): S9–S18.
23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in
healthy subjects: associations with obesity, insulin resistance, and endothelial
dysfunction: a potential role for cytokines originating from adipose tissue?
Arterioscler Thromb Vasc Biol 19: 972–978.
24. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2007) Serum amyloid
P and cardiovascular disease in older men and women: results from the
Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 27: 352–358.
25. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005)
Complement C3 is a risk factor for the development of diabetes: a
population-based cohort study. Diabetes 54: 570–575.
26. Carter AM, Prasad UK, Grant PJ (2009) Complement C3 and C-reactive
protein in male survivors of myocardial infarction. Atherosclerosis 203: 538–543.
27. Szeplaki G, Prohaszka Z, Duba J, Rugonfalvi-Kiss S, Karadi I, et al. (2004)
Association of high serum concentration of the third component of complement
(C3) with pre-existing severe coronary artery disease and new vascular events in
women. Atherosclerosis 177: 383–389.
28. Yang Y, Lu HL, Zhang J, Yu HY, Wang HW, et al. (2006) Relationships among
acylation stimulating protein, adiponectin and complement C3 in lean vs obese
type 2 diabetes. Int J Obes (Lond) 30: 439–446.
29. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, et al. (2003)
Myeloperoxidase serum levels predict risk in patients with acute coronary
syndromes. Circulation 108: 1440–1445.
30. Singh U, Devaraj S, Jialal I (2009) C-reactive protein stimulates myeloperox-
idase release from polymorphonuclear cells and monocytes: implications for
acute coronary syndromes. Clin Chem 55: 361–364.
31. Bastard JP, Pieroni L, Hainque B (2000) Relationship between plasma
plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res
Rev 16: 192–201.
32. Heidema AG, Thissen U, Boer JM, Bouwman FG, Feskens EJ, et al. (2009) The
Association of 83 Plasma Proteins with CHD Mortality, BMI, HDL-, and Total-
Cholesterol in Men: Applying Multivariate Statistics To Identify Proteins with
Prognostic Value and Biological Relevance. J Proteome Res 8: 2640–2649.
Human Protein Profiling
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14422
33. Ikonomidis I, Lekakis J, Revela I, Andreotti F, Nihoyannopoulos P (2005)
Increased circulating C-reactive protein and macrophage-colony stimulating
factor are complementary predictors of long-term outcome in patients with
chronic coronary artery disease. Eur Heart J 26: 1618–1624.
34. Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose
tissue as an endocrine and secretory organ. Proc Nutr Soc 60: 329–339.
35. Vermeulen A (1990) Plasma lipid and lipoprotein levels in obese post-
menopausal women: effects of a short-term low-protein diet and exercise.
Maturitas 12: 121–126.
36. Chang IH, Ahn SH, Han JH, Kim TH, Kim YS, et al. (2009) The clinical
significance in healthy men of the association between obesity related plasma
hemodilution and tumor marker concentration. J Urol 181: 567–572; discussion
572–563.
37. Vasudevan AR, Wu H, Xydakis AM, Jones PH, Smith EO, et al. (2006) Eotaxin
and obesity. J Clin Endocrinol Metab 91: 256–261.
38. Fenton JI, Nunez NP, Yakar S, Perkins SN, Hord NG, et al. (2009) Diet-induced
adiposity alters the serum profile of inflammation in C57BL/6N mice as
measured by antibody array. Diabetes Obes Metab 11: 343–354.
39. Kyzer S, Binyamini J, Chaimoff C, Fishman P (1999) The effect of surgically
induced weight reduction on the serum levels of the cytokines: interleukin-3 and
tumor necrosis factor. Obes Surg 9: 229–234.
40. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. (2008) Use of
multiple biomarkers to improve the prediction of death from cardiovascular
causes. N Engl J Med 358: 2107–2116.
41. Ikonomidis I, Michalakeas CA, Lekakis J, Paraskevaidis I, Kremastinos DT
(2009) Multimarker approach in cardiovascular risk prediction. Dis Markers 26:
273–285.
Human Protein Profiling
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14422
